A role for interleukin-33 in T(H)2-polarized intestinal inflammation?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A role for interleukin-33 in T(H)2-polarized intestinal inflammation? / Seidelin, J B; Rogler, G; Nielsen, O H.

In: Mucosal Immunology, Vol. 4, No. 5, 2011, p. 496-502.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Seidelin, JB, Rogler, G & Nielsen, OH 2011, 'A role for interleukin-33 in T(H)2-polarized intestinal inflammation?', Mucosal Immunology, vol. 4, no. 5, pp. 496-502. https://doi.org/10.1038/mi.2011.22

APA

Seidelin, J. B., Rogler, G., & Nielsen, O. H. (2011). A role for interleukin-33 in T(H)2-polarized intestinal inflammation? Mucosal Immunology, 4(5), 496-502. https://doi.org/10.1038/mi.2011.22

Vancouver

Seidelin JB, Rogler G, Nielsen OH. A role for interleukin-33 in T(H)2-polarized intestinal inflammation? Mucosal Immunology. 2011;4(5):496-502. https://doi.org/10.1038/mi.2011.22

Author

Seidelin, J B ; Rogler, G ; Nielsen, O H. / A role for interleukin-33 in T(H)2-polarized intestinal inflammation?. In: Mucosal Immunology. 2011 ; Vol. 4, No. 5. pp. 496-502.

Bibtex

@article{8d8abda3ea6f4bde8a85e9e871914ab5,
title = "A role for interleukin-33 in T(H)2-polarized intestinal inflammation?",
abstract = "Interleukin 33 (IL-33) is a recently discovered cytokine member of the IL-1 superfamily that is widely expressed in fixed tissue cells, including endothelial and epithelial cells. IL-33 induces helper T cells, mast cells, eosinophils, and basophils to produce type-2 cytokines through binding to the ST2/IL-1 receptor accessory protein complex. Recent studies have shown IL-33 to be upregulated in intestinal parasite infection and in epithelial cells and myofibroblasts in ulcerative colitis (UC). The findings point to a role for IL-33 in directing the T(H)2-type immune responses in these types of mucosal inflammation. As the IL-33/ST2 receptor axis can be manipulated by various blocking antibodies, this could be a potential therapeutic target in the future treatment of UC.",
author = "Seidelin, {J B} and G Rogler and Nielsen, {O H}",
year = "2011",
doi = "10.1038/mi.2011.22",
language = "English",
volume = "4",
pages = "496--502",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "nature publishing group",
number = "5",

}

RIS

TY - JOUR

T1 - A role for interleukin-33 in T(H)2-polarized intestinal inflammation?

AU - Seidelin, J B

AU - Rogler, G

AU - Nielsen, O H

PY - 2011

Y1 - 2011

N2 - Interleukin 33 (IL-33) is a recently discovered cytokine member of the IL-1 superfamily that is widely expressed in fixed tissue cells, including endothelial and epithelial cells. IL-33 induces helper T cells, mast cells, eosinophils, and basophils to produce type-2 cytokines through binding to the ST2/IL-1 receptor accessory protein complex. Recent studies have shown IL-33 to be upregulated in intestinal parasite infection and in epithelial cells and myofibroblasts in ulcerative colitis (UC). The findings point to a role for IL-33 in directing the T(H)2-type immune responses in these types of mucosal inflammation. As the IL-33/ST2 receptor axis can be manipulated by various blocking antibodies, this could be a potential therapeutic target in the future treatment of UC.

AB - Interleukin 33 (IL-33) is a recently discovered cytokine member of the IL-1 superfamily that is widely expressed in fixed tissue cells, including endothelial and epithelial cells. IL-33 induces helper T cells, mast cells, eosinophils, and basophils to produce type-2 cytokines through binding to the ST2/IL-1 receptor accessory protein complex. Recent studies have shown IL-33 to be upregulated in intestinal parasite infection and in epithelial cells and myofibroblasts in ulcerative colitis (UC). The findings point to a role for IL-33 in directing the T(H)2-type immune responses in these types of mucosal inflammation. As the IL-33/ST2 receptor axis can be manipulated by various blocking antibodies, this could be a potential therapeutic target in the future treatment of UC.

U2 - 10.1038/mi.2011.22

DO - 10.1038/mi.2011.22

M3 - Journal article

VL - 4

SP - 496

EP - 502

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 5

ER -

ID: 40182437